Search results
Results from the WOW.Com Content Network
Cystic fibrosis (also known as CF or mucoviscidosis) is an autosomal recessive genetic disorder affecting most critically the lungs, and also the pancreas, liver, and intestine.
As of 2014, believed to be the only CF patient to play any contact sport professionally. [6] Frédéric Chopin ? (unconfirmed) (1810–1849) Polish composer. During his lifetime and at his death, he was thought to suffer from tuberculosis.
Cystic Fibrosis Worldwide (CFW), [42] an international network concentrated on increasing quality of life and life expectancy for people with cystic fibrosis; CysticFibrosis.com, [43] an internet information hub with support forums
The average life expectancy, for those affected by CF, ... about one in 25 people in Northern Europe is a CF gene carrier. [3] The disease is least common in Africans ...
Cystic Fibrosis Research Institute has implemented strategies to increase awareness in underrepresented populations. [38] Though there is ongoing research about cystic fibrosis in underrepresented populations, many of the studies leave much to be desired and are not performed to the standards of studies conducted in white patients.
1080 12638 Ensembl ENSG00000001626 ENSMUSG00000041301 UniProt P13569 P26361 RefSeq (mRNA) NM_000492 NM_021050 RefSeq (protein) NP_000483 NP_066388 Location (UCSC) Chr 7: 117.29 – 117.72 Mb Chr 6: 18.17 – 18.32 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Cystic fibrosis transmembrane conductance regulator (CFTСR) is a membrane protein and anion channel in vertebrates that is ...
Dorothy Hansine Andersen (May 15, 1901 – March 3, 1963) was the American physician and researcher who first identified and named cystic fibrosis.During her almost thirty year tenure at Babies Hospital of Columbia-Presbyterian Medical Center (now Morgan Stanley Children's Hospital), Andersen not only identified CF and its inheritance through a recessive gene, she was also at the forefront of ...
Following the listing of the combination on the Pharmaceutical Benefits Scheme in 2022, the cost for people aged twelve years of age or older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene is $30.00 per month, or $7.30 for concession card holders. [48]